Lipid, Oxidative and Inflammatory Profile and Alterations in the Enzymes Paraoxonase and Butyrylcholinesterase in Plasma of Patients with Homocystinuria Due CBS Deficiency: The Vitamin B12 and Folic Acid Importance

Cellular and Molecular Neurobiology

Volumn 35, Issue 6, 2015, Pages 899-911

  Vanzin, Camila Simioni ^a,b   Mescka, Caroline Paula ^a,b   Donida, Bruna ^a,b   Hammerschimidt, Tatiane Grazieli ^b   Ribas, Graziela S ^b   Kolling, Janaína ^a   Scherer, Emilene B ^a   Vilarinho, Laura ^c   Nogueira, Célia ^c   Coitinho, Adriana Simon ^a   Wajner, Moacir ^a,b   Wyse, Angela T S ^a   Vargas, Carmen Regla ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c NATIONAL INSTITUTE OF HEALTH   (Portugal)

Author keywords

Butyrylcholinesterase; Folic acid; Homocysteine; Inflammation; Lipid profile; Paraoxonase; Vitamin B12

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; BETAINE; CHOLESTEROL; CHOLINESTERASE; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PYRIDOXINE; TRIACYLGLYCEROL; LIPID; OXIDIZING AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FEMALE; HOMOCYSTINURIA; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; YOUNG ADULT; BLOOD; CASE CONTROL STUDY; DEFICIENCY; GENETICS; PHYSIOLOGY;

ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYSTATHIONINE BETA-SYNTHASE; FEMALE; FOLIC ACID; HOMOCYSTINURIA; HUMANS; LIPIDS; MALE; OXIDANTS; OXIDATIVE STRESS; VITAMIN B 12; YOUNG ADULT;

EID: 84937513354     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-015-0185-7     Document Type: Article

References (47)

1. Aksenov MY, Markesbery WR (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer’s disease. Neurosci Lett 302:141–145
2. Aviram M, Billecke S, Sorenson R, Bisgaier CL, Newton RS, Rosenblat M et al (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18:1617–1624
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-die-binding. Anal Biochem 72:248–254
4. da Cunha AA, Ferreira AG, Wyse AT (2010) Increased inflammatory markers in brain and blood of rats subjected to acute homocysteine administration. Metab Brain Dis 25:199–206
5. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A (2003) Protein carbonylation in human diseases. Trends Mol Med 9:169–176
6. Darvesh S, Walsh R, Martin E (2007) Homocysteine thiolactone and human cholinesterases. Cell Mol Neurobiol 27:33–48
7. Devlin AM, Lentz SR (2006) ApoA-I: a missing link between homocysteine and lipid metabolism? Circ Res 98:431–433
8. Eckerson HW, Wyte CM, La Du BN (1983) The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 35:214–227
9. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M (2001) Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955–1960
10. Ellman GL, Courtney KD, Andres V, Feather-Stone RM (1961) A new and rapid determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:n19
12. Gori AM, Corsi AM, Fedi S, Gazzini A, Sofi F, Bartali B et al (2005) A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr 82:335–341
13. Gu WJ, Lu JM, Yang GQ, Guo QH, Dou JT, Mu YM et al (2007) Effects of intervention therapy of methylcobalamin and folic acid on plasma homocysteine concentration and homocysteine thiolactonase/paraoxonase activity in patients with type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi 87:256–258
14. Ishimine N, Usami Y, Nogi S, Sumida T, Kurihara Y, Matsuda K et al (2010) Identification of N-homocysteinylated apolipoprotein AI in normal human sérum. Ann Clin Biochem 47:453–459
15. Jakubowski H (2001) Protein N-homocysteinilation: implications for atherosclerosis. Biomed Pharmacother 55:443–447
16. Jakubowski H (2007) The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med 45:1704–1716
17. Jakubowski H (2008) The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 59:155–167
18. Jakubowski H, Zhang L, Berdeguez A, Aviv A (2000) Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 87:45–51
19. Jakubowski H, Ambrosius WT, Pratt JH (2001) Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 491:35–39
20. Jakubowski H, Boers GH, Strauss KA (2008) Mutations in cystathionine β-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J 22:4071–4076
21. Jiang H, Stabler SP, Allen RH, Maclean KN (2012) Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: possible implications for cardiovascular outcomes. Mol Genet Metab 107:55–65
22. Keating AK, Freehauf C, Jiang H, Brodsky GL, Stabler SP, Allen RH et al (2011) Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria. Mol Genet Metab 103:330–337
23. 12 deficiency anemia. Pediatr Hematol Oncol 29:345–353
24. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464–478
25. Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J et al (2006) Hyperhomocysteinemia decreases circulating highdensity lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99:598–606
26. Mack A, Robitzki A (2000) The key role of butyrylcholinesterase during neurogenesis and neural disorders: an antisense-5′-butyrylcholinesterase-DNA study. Prog Neurobiol 60:607–628
27. Magera MJ, Lacey JM, Casetta B, Rinaldo P (1999) Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 45:1517–1522
28. McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–128
29. Mikael LG, Genest J Jr, Rozen R (2006) Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 98:564–571
30. Mudd SH, Levy HL, Kraus JP (2001) Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 2007–2056
31. Nishio E, Watanabe Y (1997) Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols. Biochem Biophys Res Commun 236:289–293
32. Nuño-Ayala M, Guillén N, Navarro MA, Lou-Bonafonte JM, Arnal C, Gascón S et al (2010) Cysteinemia, rather than homocysteinemia, is associated with plasma apolipoprotein A-I levels in hyperhomocysteinemia: lipid metabolism in cystathionine beta-synthase deficiency. Atherosclerosis 212:268–273
33. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511
34. Perla-Kaján J, Jakubowski H (2010) Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 24:931–936
35. Perla-Kaján J, Jakubowski H (2012) Paraoxonase 1 and homocysteine metabolism. Amino Acids 43:1405–1417
36. Perla-Kaján J, Twardowski T, Jakubowski H (2007) Mechanisms of homocysteine toxicity in humans. Amino Acids 32:561–572
37. Prody CA, Zevin-Sonkin D, Gnatt A, Golberg O, Soreq H (1987) Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci USA 84:3555–3559
38. Qujeq D, Omran TS, Hosini L (2001) Correlation between total homocysteine, low density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 34:97–101
39. Santarpia L, Grandone I, Contaldo F, Pasanisi F (2013) Butyrylcholinesterase as a prognostic marker: a review of the literature. J Cachexia Sarcopenia Muscle 4:31–39
40. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129–146
41. Stefanello FM, Zugno AI, Wannmacher CMD, Wajner M, Wyse ATS (2003) Homocysteine inhibits butyrylcholinesterase activity in rat serum. Metab Brain Dis 18:187–194
42. Stefanello FM, Franzon R, Tagliari B, Wannmacher CMD, Wajner M, Wyse ATS (2005) Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia. Metab Brain Dis 20:97–103
43. Vanzin CS, Biancini GB, Sitta A, Wayhs CAY, Pereira IN, Rockenbach F et al (2011) Experimental evidence of oxidative stress in plasma of homocystinuric patients: a possible role for homocysteine. Mol Genet Metab 104:112–117
44. Weijun G, Juming L, Guoqing Y, Jingtao D, Qinghua G, Yiming M et al (2008) Effects of plasma homocysteine levels on serum HTASE/PON activity in patients with type 2 diabetes. Adv Ther 25:884–893
45. Xiao Y, Zhang Y, Lv X, Su D, Li D, Xia M et al (2011) Relationship between lipid profiles and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects. Lipids Health Dis 10:137
46. Yap S (2003) Classical homocystinuria: vascular risk and its prevention. J Inherit Metab Dis 26:259–265
47. Yap S, Boers GHJ, Wilcken B, Wilcken DEL, Brenton DP, Lee PJ et al (2001) Vascular outcome in patients with homocystinuria due to cystathionine ß-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21:2080–2085